Profile data is unavailable for this security.
About the company
RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its drug discovery and development engine, it develops selective small molecules designed to modulate the critical immune responses underlying these diseases. Its lead inflammation drug candidate, zelnecirnon (RPT193), and its lead oncology drug candidate, tivumecirnon (FLX475), each target C-C motif chemokine receptor 4 (CCR4), a drug target that potentially has broad applicability in inflammatory diseases and oncology. Its inflammation drug candidate, zelnecirnon, is designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its oncology drug candidate, tivumecirnon, is designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-116.80m
- Incorporated2015
- Employees131.00
- LocationRAPT Therapeutics Inc561 Eccles AveSOUTH SAN FRANCISCO 94080-1906United StatesUSA
- Phone+1 (650) 489-9000
- Fax+1 (302) 531-3150
- Websitehttps://rapt.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Black Diamond Therapeutics Inc | 0.00 | -82.44m | 259.62m | 54.00 | -- | 2.22 | -- | -- | -1.92 | -1.92 | 0.00 | 2.26 | 0.00 | -- | -- | 0.00 | -52.37 | -40.29 | -58.91 | -43.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.57 | -- | -15.37 | -- |
| Invivyd Inc | 0.00 | -198.64m | 261.09m | 94.00 | -- | 1.36 | -- | -- | -1.81 | -1.81 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -64.88 | -- | -73.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
| TriSalus Life Sciences Inc | 18.51m | -63.28m | 263.30m | 112.00 | -- | -- | -- | 14.22 | -1.84 | -1.84 | 0.5991 | -0.982 | 0.7758 | 1.30 | 7.24 | 165,267.90 | -247.43 | -- | -17,440.77 | -- | 85.93 | -- | -318.95 | -- | 1.25 | -13.69 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Pyxis Oncology Inc | 0.00 | -73.79m | 263.34m | 50.00 | -- | 1.61 | -- | -- | -1.87 | -1.87 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -38.32 | -- | -45.03 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.87 | -- | -- | -- |
| Werewolf Therapeutics Inc | 19.94m | -37.37m | 263.99m | 47.00 | -- | 2.14 | -- | 13.24 | -1.05 | -1.05 | 0.5595 | 2.85 | 0.119 | -- | 4.82 | 424,319.20 | -22.30 | -- | -25.62 | -- | -- | -- | -187.37 | -- | -- | -- | 0.2609 | -- | 21.60 | -- | 30.56 | -- | -- | -- |
| GeneDx Holdings Corp | 202.57m | -175.77m | 270.70m | 1.00k | -- | 1.18 | -- | 1.34 | -7.51 | -7.51 | 8.34 | 8.78 | 0.4454 | 10.03 | 5.40 | 202,566.00 | -38.64 | -- | -49.75 | -- | 44.43 | 11.50 | -86.77 | -121.10 | 2.95 | -- | 0.2425 | -- | -13.69 | 8.72 | 67.98 | -- | 7.77 | -- |
| Inozyme Pharma Inc | 0.00 | -71.17m | 271.18m | 59.00 | -- | 1.93 | -- | -- | -1.39 | -1.39 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -41.86 | -45.00 | -45.82 | -48.90 | -- | -- | -- | -- | -- | -- | 0.2417 | -- | -- | -- | -6.13 | -- | 2.85 | -- |
| Rapt Therapeutics Inc | 0.00 | -116.80m | 273.53m | 131.00 | -- | 1.84 | -- | -- | -3.05 | -3.05 | 0.00 | 4.27 | 0.00 | -- | -- | 0.00 | -53.15 | -46.30 | -57.90 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| Monte Rosa Therapeutics Inc | 0.00 | -135.35m | 275.85m | 133.00 | -- | 1.54 | -- | -- | -2.64 | -2.64 | 0.00 | 3.57 | 0.00 | -- | -- | 0.00 | -41.90 | -- | -47.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.75 | -- | -- | -- |
| Vanda Pharmaceuticals Inc. | 192.64m | 2.51m | 276.18m | 203.00 | 109.46 | 0.5068 | 50.04 | 1.43 | 0.0439 | 0.0439 | 3.35 | 9.47 | 0.3004 | 11.60 | 5.69 | 948,965.50 | 0.3912 | 6.61 | 0.4547 | 7.62 | 92.32 | 90.55 | 1.30 | 15.18 | 4.92 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| ESSA Pharma Inc | 0.00 | -25.80m | 283.12m | 50.00 | -- | 2.01 | -- | -- | -0.5851 | -0.5851 | 0.00 | 3.19 | 0.00 | -- | -- | 0.00 | -16.68 | -23.01 | -17.03 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
| Sanara Medtech Inc | 64.99m | -4.30m | 283.69m | 107.00 | -- | 6.26 | -- | 4.37 | -0.5219 | -0.5219 | 7.85 | 5.25 | 0.9635 | 1.90 | 8.37 | 607,381.70 | -6.58 | -17.73 | -8.17 | -22.07 | 87.92 | 88.08 | -6.83 | -17.13 | 1.04 | -18.75 | 0.1786 | -- | 41.77 | 61.93 | 45.79 | -- | 99.09 | -- |
| Enanta Pharmaceuticals Inc | 73.62m | -138.24m | 284.34m | 145.00 | -- | 1.48 | -- | 3.86 | -6.56 | -6.56 | 3.50 | 9.07 | 0.1897 | -- | 4.79 | 507,737.90 | -35.63 | -14.56 | -40.03 | -15.62 | -- | -- | -187.77 | -54.96 | -- | -- | 0.0074 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
| Sutro Biopharma Inc | 153.73m | -106.79m | 284.59m | 302.00 | -- | 1.54 | -- | 1.85 | -1.79 | -1.79 | 2.56 | 2.45 | 0.3503 | -- | 7.12 | 509,043.00 | -24.34 | -25.48 | -29.77 | -29.75 | -- | -- | -69.47 | -113.71 | -- | -- | 0.0264 | -- | 126.84 | 31.96 | 10.41 | -- | 22.61 | -- |
| Akebia Therapeutics Inc | 194.62m | -51.93m | 284.75m | 167.00 | -- | -- | -- | 1.46 | -0.2778 | -0.2778 | 1.04 | -0.1572 | 0.6512 | 2.22 | 4.89 | 1,165,407.00 | -17.37 | -37.42 | -28.19 | -56.00 | 78.76 | 69.13 | -26.68 | -82.25 | 1.03 | -7.64 | 8.46 | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
Data as of Apr 23 2024. Currency figures normalised to RAPT Therapeutics Inc's reporting currency: US Dollar USD
58.07%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 3.84m | 11.04% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 3.34m | 9.61% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.22m | 6.39% |
| Perceptive Advisors LLCas of 31 Dec 2023 | 2.14m | 6.15% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.99m | 5.72% |
| Deep Track Capital LPas of 31 Dec 2023 | 1.79m | 5.16% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 1.45m | 4.18% |
| T. Rowe Price Investment Management, Inc.as of 31 Dec 2023 | 1.28m | 3.67% |
| Great Point Partners LLCas of 31 Dec 2023 | 1.10m | 3.16% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 1.04m | 3.00% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
